GLP-1 Agonists Market Set to Triple by 2033, Driven by Diabetes, Obesity & Beyond

GLP-1 Agonists Market Set to Triple by 2033, Driven by Diabetes, Obesity & Beyond

The global glucagon-like peptide-1 (GLP-1) agonists market, valued at $31.3 billion in 2023, is on track to reach $90.6 billion by 2033, expanding at a robust CAGR of 11.2%. Initially developed for type 2 diabetes, GLP-1 agonists are rapidly reshaping treatment paradigms in obesity, cardiovascular health, and metabolic disorders—fueling one of the most dynamic pharmaceutical markets of the decade. 🔬 What Are GLP-1 Agonists? GLP-1 agonists are a…

GLP-1s are boosting demand for medical aesthetics – RamaOnHealthcare

Industry stakeholders can take steps to better understand the needs and preferences of GLP-1 patients who seek to address one—and often multiple—aesthetic

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Alcohol Use Disorder

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Alcohol Use Disorder Alcohol use disorder (AUD) is one of the most common mental health disorders globally and affects people of various ages, sexes, and socioeconomic backgrounds. The DSM-5 describes it as problematic patterns of alcohol use that cause clinically significant impairment or distress. AUD is associated with widespread consequences, including health implications like comorbid…